Phase II trial of an alternating regimen consisting of first-line modified FOLFIRINOX and Gemcitabine plus nab-Paclitaxel for patients with metastatic pancreatic cancer
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000022936
- Lead Sponsor
- Kurume University Hospital Multidisciplinary Treatment Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
1) History of hypersensitivity reaction 2) Homozygote of UGT1A1*6 or UGT1A1*28, heterozygote of UGT1A1*6 and UGT1A1*28 3) Brain metastasis 4) Pulmonary fibrosis or interstitial pneumonia 5) Active infection 6) Other severe complications, such as heart failure, renal failure, hepatic failure, active ulcer, bowel obstruction and diabetes with clinically problem 7) Active another cancer 8) Required treatment with steroid 9) History of the peripheral arterial disease (Buerger disease, episodes of claudication) 10) History of collagenosis (SLE, systemic scleroderma, polyarteritis nodosa) 11) Pregnant or possibility pregnancy or nursing women 12) Men with hope of the pregnancy of the partner 13) Mental disorder which become problem on clinical practice 14) Physician judged improper to entry this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method